284 related articles for article (PubMed ID: 27689695)
1. Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.
Greville G; McCann A; Rudd PM; Saldova R
Epigenetics; 2016 Dec; 11(12):845-857. PubMed ID: 27689695
[TBL] [Abstract][Full Text] [Related]
2. 5-AZA-dC induces epigenetic changes associated with modified glycosylation of secreted glycoproteins and increased EMT and migration in chemo-sensitive cancer cells.
Greville G; Llop E; Howard J; Madden SF; Perry AS; Peracaula R; Rudd PM; McCann A; Saldova R
Clin Epigenetics; 2021 Feb; 13(1):34. PubMed ID: 33579350
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modification boosts ovarian cancer vaccination.
Benmaamar R
Lancet Oncol; 2014 Feb; 15(2):e55. PubMed ID: 24627909
[No Abstract] [Full Text] [Related]
6. Why does chemotherapy stop affecting the cells of ovarian and breast tumors?
Kalinina EV; Chernov NN
Future Oncol; 2018 May; 14(12):1137-1140. PubMed ID: 29629566
[No Abstract] [Full Text] [Related]
7. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferase inhibitors for cancer therapy.
Brueckner B; Kuck D; Lyko F
Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.
Wang Y; Huang Z; Li B; Liu L; Huang C
Front Endocrinol (Lausanne); 2022; 13():863541. PubMed ID: 35620395
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
12. A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.
Longacre M; Snyder NA; Housman G; Leary M; Lapinska K; Heerboth S; Willbanks A; Sarkar S
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213343
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
14. Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers.
Duenas-Gonzalez A; Medina-Franco JL; Chavez-Blanco A; Dominguez-Gomez G; Fernández-de Gortari E
Expert Opin Pharmacother; 2016; 17(3):323-38. PubMed ID: 26559668
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
Singh AK; Chandra N; Bapat SA
Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Gyparaki MT; Papavassiliou AG
Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
[No Abstract] [Full Text] [Related]
18. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
Borley J; Brown R
Ann Med; 2015; 47(5):359-69. PubMed ID: 26158617
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications.
Mund C; Brueckner B; Lyko F
Epigenetics; 2006; 1(1):7-13. PubMed ID: 17998812
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation: a new research area for melatonin?
Korkmaz A; Reiter RJ
J Pineal Res; 2008 Jan; 44(1):41-4. PubMed ID: 18078446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]